Cash flow, $105 million in the second quarter, but year-to-date $159 million. And we did last quarter spend $75 million to repurchase 1.1 million shares.

Questions of the day. I guess you guys get the point. It’s margin, margin, margin since the conference call – the questions that Spencer and I have gotten. So I just wanted to take a few of these and address them this morning.

Where are they headed? The Oncology margins, I believe, for this year are going to be down by about one point year-over-year. And, again, that’s given this tremendous shift to international and emerging markets. I think going forward we are going to be able to maintain that oncology margin at that level, despite the fact that we are going to continue to see strong growth coming from these emerging markets.

Read the rest of this transcript for free on

If you liked this article you might like

PerkinElmer Takes Cautious Approach to M&A

Here's How Health-Care Reform Will Affect This Cancer Care Company

Corporate Tax Reform Could Be a Bigger Deal for This Company Than the ACA

Here Are the Biotech Stocks Moving Ahead of the Opening Bell

PerkinElmer Medical Imaging Unit Sale Could Be in the Works